The firm has seen a small handful of false positives for the test in thousands of samples run since the study, but attributed them to biological features.
The company said that Illumina and Sequenom's NIPT patents are not present in the Middle East, allowing it to sell its Iona test unimpeded.
The acquisition will expand Premaitha's market in Asia, enable it to develop new products, and strengthen its patent position in NIPT.
A hospital lab associated with Mahidol University in Thailand will now offer the firm's Iona test in that country and its neighbors.
By offering NIPT as a secondary screening test, the UK hopes to reduce the number of invasive diagnostic tests and associated miscarriages.
Premaitha said it has sold more than 17,000 of the tests, which is the focus of an ongoing patent-infringement suit, since its launch in early 2015.
During a case management conference last week, Premaitha said the EC's competition department contacted it regarding an investigation into Illumina and Sequenom.
A UK court accepted an application by Premaitha to include an antitrust claim in its defense, and has tentatively scheduled the trial for the summer of 2017.
The agreement marks the sixth Iona distribution deal Premaitha has signed with regional partners in recent months, including ones in France and India.
St. George's University Hospitals NHS Foundation Trust, which has been offering NIPT since last year, plans to double its capacity by the third quarter.
Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.
Bill Gates tells the Telegraph that bioterrorism is a serious risk.
The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.
CBS News reports that the White House Science Fair is to continue under President Donald Trump.